bioRxivCancer BiologyPreprint
Extensive and differential platinum chemotherapy mutagenesis in children
Anna WengeriD, Henry Lee-SixiD, Manàs DaveiD, Mehdi LayeghifardiD, Andrew R. J. LawsoniD, Federico AbascaliD, Pantelis A. NicolaiD, Taryn D. TregeriD, Toochi OgbonnahiD, Conor ParksiD, Thomas R. W. OliveriD, Jonathan KennedyiD, Angus HodderiD, Nathaniel D. AndersoniD, Felipe Luz Torres SilvaiD, Mi K. TrinhiD, Thomas Dowe, Marwo Habarwaa, James J. SuniD, Sergio Assia‐ZamoraiD, Miriam Cortés CerisueloiD, Wayel JassemiD, Charlotte Town, Anil Kumar DhawaniD, Vandana Jain, , Sam BehjatiiD
Abstract
Childhood cancer survivors often develop long-term adverse effects, which may be caused by direct mutagenesis of cytotoxic agents. Some of these agents generate distinctive DNA imprints (mutational signatures), as exemplified by platinum chemotherapeutics. Here, we examined chemotherapy mutagenesis in paediatric tissues by deploying a duplex sequencing method (NanoSeq), which enables mutation calling from single DNA molecules. We surveyed whole genomes of paediatric liver, blood and other tissues, obtained from surgical resections and at post-mortem. Platinum signatures pervaded all tissues extensively, elevating mutation burdens of paediatric tissues to levels seen in adults. Remarkably, we found a tissue-specific mutational signature in the liver. We examined the functional potential of mutations by gene focused NanoSeq, which revealed that platinum agents cause a vast repertoire of cancer causing variants across normal tissues, such as leukaemogenic mutations in blood. This finding may conceivably link cancer treatment in childhood to mutation-driven long term sequelae.
- organism: human
- assay: whole-genome sequencing
- research focus: chromatin & epigenetic regulation
- research focus: cancer & tumor microenvironment
- research focus: differential expression
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Copy number footprints of platinum-based anticancer therapies
Santiago González, Núria López-Bigas, Abel González-Pérez·PLoS GeneticsPeer-reviewed·Feb 13, 2023
- Cisplatin is more mutagenic than carboplatin or oxaliplatin at equitoxic concentrations
Bernadett Szikriszt, Ádám Póti, … Dávid Szüts·bioRxiv·Aug 11, 2020
- The long-term effects of chemotherapy on normal blood cells
Emily Mitchell, My H. Pham, … Michael R. Stratton·Nature GeneticsPeer-reviewed·Jul 1, 2025
- The mutational footprints of cancer therapies
Oriol Pich, Ferran Muiños, … Núria López-Bigas·Nature GeneticsPeer-reviewed·Nov 18, 2019
- In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
A. Boot, M. N. Huang, … S. G. Rozen·bioRxiv·Dec 17, 2017
- Chromosomal mutational signatures of DNA damaging agents at single cell resolution
Mirela Andronescu, Alexander Adrian-Hamazaki, … Samuel A. J. R. Aparicio·bioRxiv·Sep 7, 2026